FOLD – amicus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an "overweight" rating on the stock.
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated [Yahoo! Finance]
Form SC 13G/A AMICUS THERAPEUTICS, Filed by: Redmile Group, LLC
Form SC 13G AMICUS THERAPEUTICS, Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
Form SC 13G/A AMICUS THERAPEUTICS, Filed by: Avoro Capital Advisors LLC
Form SC 13G/A AMICUS THERAPEUTICS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Form 4 AMICUS THERAPEUTICS, For: Nov 06 Filed by: Campbell Bradley L
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.